Aytu BioPharma Inc (AYTU)
3.20
+0.02
(+0.63%)
USD |
NASDAQ |
May 24, 16:00
3.20
0.00 (0.00%)
After-Hours: 20:00
Aytu BioPharma Revenue (Quarterly): 17.99M for March 31, 2024
Revenue (Quarterly) Chart
Historical Revenue (Quarterly) Data
| Date | Value |
|---|---|
| March 31, 2024 | 17.99M |
| December 31, 2023 | 22.93M |
| September 30, 2023 | 22.10M |
| June 30, 2023 | 30.73M |
| March 31, 2023 | 22.73M |
| December 31, 2022 | 26.28M |
| September 30, 2022 | 27.66M |
| June 30, 2022 | 27.45M |
| March 31, 2022 | 24.20M |
| December 31, 2021 | 23.12M |
| September 30, 2021 | 21.90M |
| June 30, 2021 | 23.48M |
| March 31, 2021 | 13.48M |
| December 31, 2020 | 15.15M |
| September 30, 2020 | 13.52M |
| June 30, 2020 | 14.86M |
| March 31, 2020 | 8.156M |
| December 31, 2019 | 3.175M |
| September 30, 2019 | 1.440M |
| Date | Value |
|---|---|
| June 30, 2019 | 1.716M |
| March 31, 2019 | 2.378M |
| December 31, 2018 | 1.795M |
| September 30, 2018 | 1.432M |
| June 30, 2018 | 0.9251M |
| March 31, 2018 | 0.607M |
| December 31, 2017 | 1.051M |
| September 30, 2017 | 1.076M |
| June 30, 2017 | 0.836M |
| March 31, 2017 | 0.894M |
| December 31, 2016 | 0.794M |
| September 30, 2016 | 0.698M |
| June 30, 2016 | 0.9373M |
| March 31, 2016 | 0.6684M |
| December 31, 2015 | 0.4694M |
| September 30, 2015 | 0.4874M |
| June 30, 2015 | 0.182M |
| March 31, 2015 | 0.0238M |
Revenues Definition
Revenues measure the total amount of value that a company brings in during a certain period. This is also considered the "top-line" of the income statement. Revenues are used for all operating expenses as well as other line items which eventually lead to the net income for the company. Revenue is an extremely important metric when analyzing a company. A company with efficient margins is able to turn revenues into the most net income.
Revenue (Quarterly) Range, Past 5 Years
1.440M
Minimum
Sep 2019
30.73M
Maximum
Jun 2023
18.10M
Average
22.00M
Median
Revenue (Quarterly) Benchmarks
| Regen BioPharma Inc | 0.0591M |
| Clearday Inc | 0.8319M |
| Bioxytran Inc | -- |
| Shuttle Pharmaceuticals Holdings Inc | -- |
| CEL-SCI Corp | -- |
Revenue (Quarterly) Related Metrics
| Net Income (Quarterly) | -2.887M |
| Total Expenses (Quarterly) | 20.21M |
| EPS Diluted (Quarterly) | -0.52 |
| Enterprise Value | 14.76M |
| Gross Profit Margin (Quarterly) | 64.99% |
| Profit Margin (Quarterly) | -16.05% |
| Earnings Yield | -82.19% |
| Operating Earnings Yield | 8.79% |
| Normalized Earnings Yield | -17.67 |